Company Filing History:
Years Active: 2010
Title: Innovations of Zhao-Qing Wang in VEGF-R2 Inhibition
Introduction
Zhao-Qing Wang is a notable inventor based in Indianapolis, IN (US). He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that inhibit vascular endothelial growth factor receptor 2 (VEGF-R2). His work is crucial in the fight against various diseases, including cancer.
Latest Patents
Zhao-Qing Wang holds a patent for "Imidazo[1,2-A]pyridine compounds as VEGF-R2 inhibitors." This invention provides compounds that serve as inhibitors of VEGF-R2, with a specific formula and methods for utilizing these compounds effectively. His innovative approach has the potential to lead to new therapeutic options for patients.
Career Highlights
Wang is currently employed at Eli Lilly and Company, a leading global pharmaceutical company. His role involves research and development, where he applies his expertise to create novel therapeutic agents. His dedication to advancing medical science is evident in his work and the impact it has on patient care.
Collaborations
Zhao-Qing Wang collaborates with esteemed colleagues, including David Anthony Barda and Timothy Paul Burkholder. These partnerships enhance the research efforts at Eli Lilly and Company, fostering an environment of innovation and discovery.
Conclusion
Zhao-Qing Wang's contributions to the field of VEGF-R2 inhibition exemplify the importance of innovation in medicine. His work not only advances scientific knowledge but also holds promise for improving patient outcomes.